This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
JACC Specialty Journals
JACC: CardioOncology - Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients with Transthyretin Amyloid Cardiomyopathy
Released: Oct 19, 2021
Commentary by Dr. Martha Grogan
JACC: CardioOncology - Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients with Transthyretin Amyloid Cardiomyopathy
00:00:00
